Daniel Hein

Essen, NW, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications

H1-0 is a specific mediator of the repressive ETV6::RUNX1 transcriptional landscape in preleukemia and B cell acute lymphoblastic leukemia.

H1-0 is a specific mediator of the repressive ETV6::RUNX1 transcriptional landscape in preleukemia and B cell acute lymphoblastic leukemia.

Journal: HemaSphere
Published: July 04, 2024

Cytokine Hyperresponsiveness in Children With ETV6::RUNX1-positive Acute Lymphoblastic Leukemia After Challenge With Common Pathogens.

Cytokine Hyperresponsiveness in Children With ETV6::RUNX1-positive Acute Lymphoblastic Leukemia After Challenge With Common Pathogens.

Journal: HemaSphere
Published: August 10, 2022

In Utero Development and Immunosurveillance of B Cell Acute Lymphoblastic Leukemia.

In Utero Development and Immunosurveillance of B Cell Acute Lymphoblastic Leukemia.

Journal: Current treatment options in oncology
Published: February 10, 2022

Cell Fate Decisions: The Role of Transcription Factors in Early B-cell Development and Leukemia.

Cell Fate Decisions: The Role of Transcription Factors in Early B-cell Development and Leukemia.

Journal: Blood cancer discovery
Published: January 04, 2021

Genomic Inverse PCR for Screening of Preleukemic Cells in Newborns (GIPFEL Technology).

Genomic Inverse PCR for Screening of Preleukemic Cells in Newborns (GIPFEL Technology).

Journal: Methods in molecular biology (Clifton, N.J.)
Published: November 09, 2020

Insights into the prenatal origin of childhood acute lymphoblastic leukemia.

Insights into the prenatal origin of childhood acute lymphoblastic leukemia.

Journal: Cancer metastasis reviews
Published: January 06, 2020

An intact gut microbiome protects genetically predisposed mice against leukemia.

An intact gut microbiome protects genetically predisposed mice against leukemia.

Journal: Blood
Published: December 03, 2019

The preleukemic TCF3-PBX1 gene fusion can be generated in utero and is present in ≈0.6% of healthy newborns.

The preleukemic TCF3-PBX1 gene fusion can be generated in utero and is present in ≈0.6% of healthy newborns.

Journal: Blood
Published: August 23, 2019

Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets.

Pediatric ALL relapses after allo-SCT show high individuality, clonal dynamics, selective pressure, and druggable targets.

Journal: Blood advances
Published: February 19, 2019
Showing 1-9 of 9

Last Updated: 09/26/2026